^
Association details:
| Biomarker: | IFNA1 expression |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of an immune gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC).
Published date:
02/14/2020
Excerpt:
...investigated immune transcriptome signatures and molecular subtyping as potential predictors of pembro efficacy. ...pathologic complete responses (pT0)...IFN-γ (OR: 1.10, 95%CI: 1-1.2, p=0.007) and IFN-α response (OR: 1.07, 95%CI: 1-1.1, p=0.009) were also associated with pT0 for PURE01.
Trial ID: